These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15389251)

  • 1. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
    Logani S; Oliva E; Arnell PM; Amin MB; Young RH
    Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
    Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
    Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
    Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
    Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
    Kim MJ
    J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
    Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
    Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
    McCluggage WG; Young RH
    Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Suh N; Yang XJ; Tretiakova MS; Humphrey PA; Wang HL
    Mod Pathol; 2005 Sep; 18(9):1217-22. PubMed ID: 15803184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
    Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
    Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
    Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
    Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
    Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.
    Albarracin CT; Jafri J; Montag AG; Hart J; Kuan SF
    Hum Pathol; 2000 Jun; 31(6):672-7. PubMed ID: 10872659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
    Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
    Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
    Baker PM; Oliva E
    Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.